{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:12:16Z","timestamp":1766139136115,"version":"3.41.2"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure, characterized by a poor prognosis, managed with surgery, chemotherapy and radiotherapy. Recently, immunotherapy gives a survival advantage compared to chemotherapy, but limited to the non-epithelioid histotype, the rarest type. Radical hemithorax radiotherapy (RHRT) improves the Overall Survival (OS) of MPM patients, irrespective of histotype, and is able to induce immunomodulatory effects. In this study we aim to investigate changes in circulating T lymphocytes phenotype and activity, in MPM patients undergoing RHRT, to evaluate a possible therapeutic space for immunotherapy in this setting. To assess immunomodulatory effects of RHRT we evaluate peripheral blood samples of 35 MPM patients collected before treatment, at the end of RT, and 1 month later. We first notice that higher Lymphocyte-to-Monocyte Ratio (LMR) levels, before RT, are associated with an improved OS. The immune monitoring performed by ELISA assays reveals a significant increase in the serum levels of soluble PD-L1 (sPD-L1) and IFN\u2010\u03b3 at the end of RHRT. Furthermore, the percentage of PD\u20101<jats:sup>+<\/jats:sup> cells, evaluated by flow cytometry, significantly raise after RHRT in T cells, both CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup>. Also the proportion of proliferative cells is significantly expanded after RHRT in all T cell subtypes. After treatment we observe a significant increase in the number of patients showing WT-1 specific CD4<jats:sup>+<\/jats:sup> T cells, measured by intracellular staining. The TCR repertoire analysis, investigated by Next Generation Sequencing, reveals an increased number of expanded T-cell clones after RHRT, and an association between TCR clonality and the percentage of proliferating cytotoxic T lymphocytes. The comparison of TCR sequences obtained in our cohort with those described in a literature cohort of MPM patients, reveals common entries, specific for MPM-associated antigens including WT-1. In this setting, pre-treatment levels of LMR seem to have a positive prognostic role, and RHRT would appear to induce immunomodulating effects, potential biomarkers for immunotherapy eligibility: i.e. increased PD-1<jats:sup>+<\/jats:sup> T lymphocytes, proliferating T cells, expanded T cell clones and augmented levels of sPD-L1. These data suggest the design of a prospective study evaluating a maintenance immunotherapy after RHRT in MPM, even in the epithelioid histotype.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1534766","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:58:22Z","timestamp":1743497902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1\/PD-L1 targeting treatment?"],"prefix":"10.3389","volume":"16","author":[{"given":"Alberto","family":"Revelant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gessoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Montico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Dhibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Brisotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariateresa","family":"Casarotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Paduano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Giordari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valli","family":"De Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Trov\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Minatel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Mascarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Steffan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Muraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B2","unstructured":"Thoracic tumours"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in Malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for Malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with Malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0169-5002(03)91714-4","article-title":"O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of Malignant pleural mesothelioma","volume":"41","author":"Boyer","year":"2003","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with Malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I\u2013III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with Malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"Ghanim","year":"2020","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed Malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent Malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"A randomized phase II trial of oral vinorelbine as second-line therapy for patients with Malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated Malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318272601f","article-title":"Tomotherapy after pleurectomy\/decortication or biopsy for Malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung","volume":"7","author":"Minatel","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.03.011","article-title":"Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for Malignant pleural mesothelioma","volume":"69","author":"Rice","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of Malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for Malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with Malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.04.025","article-title":"Heart dosimetry is correlated with risk of radiation pneumonitis after lung-sparing hemithoracic pleural intensity modulated radiation therapy for Malignant pleural mesothelioma","volume":"99","author":"Yorke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for Malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25016","article-title":"Treg(s) in cancer: friends or foe","volume":"230","author":"Wolf","year":"2015","journal-title":"J Cell Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023119","article-title":"Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell\u2013mediated remissions","volume":"2","author":"Dutt","year":"2018","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.09.079","article-title":"Emerging role of immunomonitoring to predict the clinical outcome of patients with Malignant pleural mesothelioma treated with radical radiation therapy","volume":"115","author":"Cangemi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100808","article-title":"The paradox of radiation and T cells in tumors","volume":"31","author":"Gough","year":"2022","journal-title":"Neoplasia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.057","article-title":"Radical hemithoracic radiotherapy versus palliative radiotherapy in non-metastatic Malignant pleural mesothelioma: results from a phase 3 randomized clinical trial","volume":"109","author":"Trovo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/2326-6066.CIR-13-0079","article-title":"Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunity","volume":"1","author":"Laske","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3822","article-title":"Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire","volume":"49","author":"Emerson","year":"2017","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5301\/JBM.2011.8903","article-title":"KIR\/HLA combination associated with the risk of complications in celiac disease","volume":"26","author":"Caggiari","year":"2011","journal-title":"Int J Biol Markers"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msy116","article-title":"Divergent allele advantage at human MHC genes: signatures of past and ongoing selection","volume":"35","author":"Pierini","year":"2018","journal-title":"Mol Biol Evol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.530208.x","article-title":"Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop","volume":"53","author":"Tonks","year":"1999","journal-title":"Tissue Antigens"},{"key":"B43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1399-0039.2005.00345.x","article-title":"New strategies for efficient typing of HLA class-II loci DQB1 and DRB1 by using Pyrosequencing","volume":"65","author":"Entz","year":"2005","journal-title":"Tissue Antigens"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088133","article-title":"Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.thj.6200220","article-title":"Synthetic peptides derived from the Wilms\u2019 tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells","volume":"4","author":"M\u00fcller","year":"2003","journal-title":"Hematol J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1488851","article-title":"A large-scale database of T-cell receptor beta sequences and binding associations from natural and synthetic exposure to SARS-CoV-2","volume":"16","author":"Nolan","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006035","article-title":"Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy","volume":"11","author":"Desai","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01578-0","article-title":"VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2","volume":"19","author":"Goncharov","year":"2022","journal-title":"Nat Methods"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx286","article-title":"McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences","volume":"33","author":"Tickotsky","year":"2017","journal-title":"Bioinformatics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640725","article-title":"TCRMatch: predicting T-cell receptor specificity based on sequence similarity to previously characterized receptors","volume":"12","author":"Chronister","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2222560","article-title":"Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference","volume":"12","author":"Gregucci","year":"2023","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00229","article-title":"Barriers to radiation-induced in situ tumor vaccination","volume":"8","author":"Wennerberg","year":"2017","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2024.04.004","article-title":"The effects of radiation dose heterogeneity on the tumor microenvironment and anti-tumor immunity","volume":"34","author":"Takashima","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in Malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ Health Prev Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with Malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02936-2","article-title":"Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy","volume":"25","author":"Chen","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21703","article-title":"Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy - A single center experience","volume":"9","author":"Luo","year":"2018","journal-title":"J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.4.915","article-title":"Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression","volume":"174","author":"de Waal Malefyt","year":"1991","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000487","article-title":"Foxp3+ Regulatory T cell depletion after nonablative oligofractionated irradiation boosts the abscopal effects in murine Malignant mesothelioma","volume":"205","author":"Kohno","year":"2020","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.04.009","article-title":"Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells","volume":"1846","author":"Heylmann","year":"2014","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: A paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00090","article-title":"Regulatory T cells in radiotherapeutic responses","volume":"2","author":"Schaue","year":"2012","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.05.003","article-title":"Interleukin-10 in cancer immunotherapy: from bench to bedside","volume":"9","author":"Salkeni","year":"2023","journal-title":"Trends Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225725","article-title":"Changes in blood biomarkers of angiogenesis and immune modulation after radiation therapy and their association with outcomes in thoracic Malignancies","volume":"13","author":"Gkika","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020493","article-title":"Immune marker expression of irradiated mesothelioma cell lines","volume":"12","author":"Chang","year":"2022","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179414","article-title":"Peripheral blood-based biomarkers for immune checkpoint inhibitors","volume":"22","author":"An","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807696","article-title":"Revealing clonal responses of tumor-reactive T-cells through T cell receptor repertoire analysis","volume":"13","author":"Aoki","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for Malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163932","article-title":"Hitting the bull\u2019s-eye: mesothelin\u2019s role as a biomarker and therapeutic target for Malignant pleural mesothelioma","volume":"13","author":"Yeo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00432-023-05565-6","article-title":"BAP1, Wilms\u2019 tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma","volume":"150","author":"Yuce","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01476","article-title":"Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer","volume":"8","author":"Muraro","year":"2017","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2001933117","article-title":"Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients","volume":"117","author":"Chow","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1038\/s41598-017-04978-x","article-title":"Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-023-00358-z","article-title":"Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer","volume":"7","author":"Gkika","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316691","article-title":"Modulation of CD8+ T cell responses by radiotherapy-current evidence and rationale for combination with immune checkpoint inhibitors","volume":"24","author":"Jeon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00245-1","article-title":"Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer","volume":"2","author":"Ban","year":"2021","journal-title":"Nat Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.028","article-title":"Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer","volume":"143","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00547","article-title":"Spontaneous T cell proliferation: A physiologic process to create and maintain homeostatic balance and diversity of the immune system","volume":"9","author":"Min","year":"2018","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.138","article-title":"Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of Malignant mesothelioma","volume":"8","author":"Sobhani","year":"2017","journal-title":"Genes Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational profiling of Malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-018-0517-9","article-title":"Assessment of new HDAC inhibitors for immunotherapy of Malignant pleural mesothelioma","volume":"10","author":"Bensaid","year":"2018","journal-title":"Clin Epigenet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of Malignant pleural mesothelioma: results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of Malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.025","article-title":"Splicing modulation as novel therapeutic strategy against diffuse Malignant peritoneal mesothelioma","volume":"39","author":"Sciarrillo","year":"2019","journal-title":"EBioMedicine"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307204","article-title":"Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid Malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study","volume":"19","author":"Van den Bossche","year":"2024","journal-title":"PloS One"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with Malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207516120","article-title":"Inferring the T cell repertoire dynamics of healthy individuals","volume":"120","author":"Bensouda Koraichi","year":"2023","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200921","article-title":"Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells","volume":"218","author":"Lucca","year":"2021","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ Activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1534766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:58:24Z","timestamp":1743497904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1534766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2025.1534766"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1534766","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1534766"}}